BTN3A2

BTN3A2 is a butyrophilin-family transmembrane protein that functions as the antigen-presenting arm of a phosphoantigen-sensing complex and operates more broadly as a context-dependent regulator of cell-surface signaling and stress responses [PMID:bio_10.1101_2024.10.02.616253]. In Vγ9Vδ2 T-cell immune surveillance, BTN3A2 assembles into a full-length complex with BTN3A1 and BTN2A1; phosphoantigen (HMBPP) bridges the intracellular B30.2 domains of BTN3A1 and BTN2A1, and upon T-cell receptor engagement the BTN3A2–BTN2A1 ectodomain interaction dissociates so that BTN3A2 binds the apical surface of the Vδ2 chain, establishing it as a bona fide TCR ligand acting through a 'pliers-like gripping' activation mechanism [PMID:bio_10.1101_2024.10.02.616253]. Beyond immunity, BTN3A2 engages diverse cell-surface and secreted partners: it binds presynaptic neurexins and suppresses excitatory synaptic transmission onto hippocampal neurons (PMID:31133542); it interacts with both ACE2 and the SARS-CoV-2 Spike receptor-binding domain and restricts viral attachment by lowering ACE2 levels (PMID:39142074); and it binds MFGE8, downregulating it to promote hypoxia-induced ferroptosis and inhibit angiogenesis (PMID:40147528). BTN3A2 is also a hypoxia-responsive gene directly activated by HIF-1α that drives temozolomide chemoresistance in glioma through an AKT/SP1/RAD51 DNA-damage-repair axis (PMID:41965757), and its expression supports gastric cancer cell proliferation, migration, and invasion (PMID:28246015).

1. 2017 Medium

   Established that BTN3A2 expression is functionally pro-tumorigenic and genetically regulated, addressing whether the locus contributes causally to cancer cell behavior rather than being a bystander.

   Evidence CRISPR/Cas9 deletion with proliferation/migration/invasion readouts plus enhancer reporter assay at rs1679709 in gastric cancer cells

   PMID:28246015

   Open questions at the time

   • No molecular partner or signaling pathway linking BTN3A2 to the cancer phenotype identified
   • Single lab, gastric cancer only
2. 2019 Medium

   Identified a non-immune neuronal role, showing BTN3A2 binds presynaptic neurexins and modulates synaptic transmission, expanding its function beyond the immune system.

   Evidence Hippocampal slice electrophysiology with BTN3A2 overexpression and cell-surface neurexin binding assay in rat

   PMID:31133542

   Open questions at the time

   • Mechanism by which neurexin binding suppresses excitatory transmission unresolved
   • Endogenous loss-of-function not tested
   • Binding stoichiometry/affinity not defined
3. 2024 High

   Defined an antiviral function, showing BTN3A2 binds both the SARS-CoV-2 Spike RBD and ACE2 and restricts infection by reducing ACE2 levels.

   Evidence Co-IP, biolayer interferometry, competition ELISA, flow cytometry in edited cell lines, and transgenic mice infected with live SARS-CoV-2

   PMID:39142074

   Open questions at the time

   • Molecular basis of ACE2 downregulation (degradation vs. trafficking) not resolved
   • Whether antiviral activity generalizes beyond SARS-CoV-2 unknown
4. 2024 High

   Resolved the structural mechanism of phosphoantigen sensing, confirming BTN3A2 as a direct Vγ9Vδ2 TCR ligand within the BTN3A1–BTN3A2–BTN2A1 complex.

   Evidence Cryo-EM structures of full-length complexes in primed and TCR-engaged states stabilized by HMBPP (preprint)

   PMID:bio_10.1101_2024.10.02.616253

   Open questions at the time

   • Preprint, not peer-reviewed
   • Dynamics of the primed-to-engaged transition in cells not directly observed
   • Quantitative contribution of BTN3A2 vs BTN2A1 to TCR triggering not separated
5. 2025 Medium

   Linked BTN3A2 to vascular biology, showing its interaction with MFGE8 drives hypoxia-induced ferroptosis and anti-angiogenic effects.

   Evidence Co-IP, siRNA knockdown and overexpression in HUVECs, and a rat preeclampsia model in vivo

   PMID:40147528

   Open questions at the time

   • How BTN3A2 binding downregulates MFGE8 is undefined
   • Connection to ferroptosis machinery not mechanistically dissected
   • Single lab
6. 2026 Medium

   Placed BTN3A2 within hypoxic transcriptional control and DNA-repair-mediated chemoresistance, identifying it as a HIF-1α target driving temozolomide resistance.

   Evidence RNA-seq, CUT&Tag, promoter luciferase, and lentiviral knockdown in glioma cells and in vivo TMZ sensitivity assays

   PMID:41965757

   Open questions at the time

   • Mechanism connecting cell-surface BTN3A2 to intracellular AKT/SP1/RAD51 signaling unclear
   • Direct vs indirect activation of the AKT axis not established
   • Single lab, glioma only

• How a single butyrophilin reconciles its membrane-receptor functions (TCR ligand, neurexin/ACE2/MFGE8 binding) with intracellular signaling outputs (AKT/SP1/RAD51) remains unresolved.
• No unifying mechanism links surface binding events to downstream intracellular pathways
• Tissue-specific partner selection not understood
• Physiological vs pathological roles not integrated